

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

LISTING OF CLAIMS:

-- Claim 1. (Original)

A method for inhibiting 5-lipoxygenase in a subject, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to the subject in an amount effective for the inhibition of 5-lipoxygenase:



(I)

wherein


X is CH or N;

Y is S or O;

R¹ is H, OH, halogen, C₁₋₆ alkyl, nitro, cyano, amino, di-C₁₋₆ alkylamino, C₁₋₆ alkoxy, C₁₋₆ hydroxyalkyl or C₁₋₆ alkylcarbonyl; and


R² is

(i)




wherein R³ is H or C₁₋₆ alkyl;

R⁴ is




wherein R⁵, R⁶, R⁷, R⁸ and R⁹ are independently H, OH, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, nitro, cyano, amino, di-C₁₋₆ alkylamino, mercapto, C₁₋₆ mercaptoalkyl, halogen-substituted C₁₋₆ mercaptoalkyl, phenylazo, C₁₋₆ alkylphenylazo, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy or C₁₋₆ hydroxyalkyl,

(ii)




wherein R^5 , R^6 , R^7 , R^8 and R^9 are as defined in (i),

(iii)




wherein R^{10} is H or C_{1-6} alkyl,

(iv)



wherein R^{11} is H, C_{1-6} alkyl, halogen, mercapto or C_{1-6} mercaptoalkyl, or

(v)



wherein R^{12} is H, OH, halogen, C_{1-6} alkyl, nitro, cyano, amino, di- C_{1-6} alkylamino, C_{1-6} alkylcarbonyl, C_{1-6} alkoxy or C_{1-6} hydroxyalkyl.

-- Claim 2. (Original)


The method of claim 1, which is used for preventing or treating a leukotriene-related disease selected from the group consisting of: asthma, pertussis, psoriasis, rheumatic arthritis, arthritis, inflammatory bowel disease, cystic fibrosis, acute/chronic bronchitis, gout, sepsis, cardiac myoischemia, cardiac anaphylaxis, cerebrovascular convulsion, ischemia and allergic rhinitis.

-- Claim 3. (Original)

The method of claim 2, wherein the disease is asthma.

-- Claim 4. (Original)

The method of claim 1, wherein R² is







wherein R³, R⁵, R⁶, R⁷, R⁸ and R⁹ are as defined in claim 1.

-- Claim 5. (Original)


The method of claim 4, wherein R¹ is H, halogen, C₁₋₆ alkyl or nitro; and R⁵, R⁶, R⁷, R⁸ and R⁹ are independently H, halogen, C₁₋₆ alkyl or phenylazo.



-- Claim 6. (Original)
The method of claim 1, wherein R^2 is



wherein R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} are as defined in claim 1.

-- Claim 7. (Original)
The method of claim 6, wherein R^1 is H or C_{1-6} alkyl; and R^2 is






wherein R^5 , R^6 , R^7 , R^8 and R^9 are, independently, H, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, nitro, cyano, amino, di- C_{1-6} alkylamino, mercapto, C_{1-6} mercaptoalkyl, halogen-substituted C_{1-6} mercaptoalkyl or C_{1-6} alkoxy;

R^{11} is as defined in claim 1; and

R^{12} is H, halogen or C_{1-6} alkyl.


-- Claim 8. (Amended)

A method for preparing a compound of formula (I)




(I)


comprising the steps of: (a) reacting a compound of formula (II) with a compound of formula (III) in an organic solvent to synthesize a thiourea intermediate of formula (IV); and (b) reacting the thiourea intermediate of formula (IV) with an acid to obtain a compound of formula (Ia) or (Ib):




(II)




(III)



(IV)



(Ia)



(Ib)

wherein ~~R1, R3, R5, R6, R7, R8 and R9~~ are as defined in claim 1.

R¹ is H, OH, halogen, C₁₋₆ alkyl, nitro, cyano, amino, di-C₁₋₆ alkylamino, C₁₋₆ alkoxy, C₁₋₆ hydroxyalkyl or C₁₋₆ alkylcarbonyl; and

wherein R³ is H or C₁₋₆ alkyl;

wherein R⁵, R⁶, R⁷, R⁸ and R⁹ are independently H, OH, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, nitro, cyano, amino, di-C₁₋₆ alkylamino, mercapto, C₁₋₆ mercaptoalkyl, halogen-substituted C₁₋₆ mercaptoalkyl, phenylazo, C₁₋₆ alkylphenylazo, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy or C₁₋₆ hydroxyalkyl.

-- Claim 9. (Original)

The method of claim 8, wherein the acid in step (b) is selected from the group consisting of trifluoroacetic acid, phosphoric acid, sulfuric acid, hydrochloric acid and nitric acid.